| Literature DB >> 28247570 |
Xiaolong Wang1, Lei Sun2, Xijing Wang1, Huafeng Kang1, Xiaobin Ma1, Meng Wang1, Shuai Lin1, Meng Liu1, Cong Dai1, Zhijun Dai1.
Abstract
c-Myc overexpression has been implicated in several malignancies including gastric cancer. Here, we report that acidified bile acids enhance tumor progression and telomerase activity in gastric cancer via c-Myc activation both in vivo and in vitro. c-Myc mRNA and protein levels were assessed in ten primary and five local recurrent gastric cancer samples by quantitative real-time polymerase chain reaction and western blotting analysis. The gastric cancer cell line MGC803 was exposed to bile salts (100 μmol/L glycochenodeoxycholic acid and deoxycholic acid) in an acid medium (pH 5.5) for 10 min daily for 60 weeks to develop an MGC803-resistant cell line. Control MGC803 cells were grown without acids or bile salts for 60 weeks as a control. Cell morphology, proliferation, colony formation and apoptosis of MGC803-resistant cells were analyzed after 60 weeks. To determine the involvement of c-Myc in tumor progression and telomere aging in MGC803-resistant cells, we generated xenografts in nude mice and measured xenograft volume and in vivo telomerase activity. The c-Myc and hTERT protein and mRNA levels were significantly higher in local recurrent gastric cancer samples than in primary gastric cancer samples. MGC803-resistant cells showed a marked phenotypic change under normal growth conditions with more clusters and acini, and exhibited increased cell viability and colony formation and decreased apoptosis in vitro. These phenotypic changes were found to be dependent on c-Myc activation using the c-Myc inhibitor 10058-F4. MGC803-resistant cells also showed a c-Myc-dependent increase in xenograft growth and telomerase activity in vivo. In conclusion, these observations support the hypothesis that acidified bile acids enhance tumor progression and telomerase activity in gastric cancer and that these effects are dependent on c-Myc activity. These findings suggest that acidified bile acids play an important role in the malignant progression of local recurrent gastric cancer.Entities:
Keywords: Acidified bile acids; c-Myc activation; duodenal reflux; gastric cancer; telomerase activity
Mesh:
Substances:
Year: 2017 PMID: 28247570 PMCID: PMC5387128 DOI: 10.1002/cam4.999
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Primer sequences
| Gene | Sequence | PCR product |
|---|---|---|
| c‐Myc | 5′‐ TCAAGAGGTGCCACGTCTCC ‐3′ | 81 bp |
| 5′‐ TCTTGGCAGCAGGATAGTCCTT ‐3′ | ||
| hTERT | 5′‐ ATCAGACAGCACTTGAAGAG‐3′ | 150 bp |
| 5′‐ GTAGTCCATGTTCACAATCG ‐3′ | ||
|
| 5′‐ CTTAGCACCCCTGGCCAAG ‐3′ | 151 bp |
| 5′‐ GATGTTCTGGAGAGCCCCG ‐3′ |
Figure 1c‐Myc and hTERT expression in primary gastric cancer and local recurrent gastric cancer samples. (A) Western blot analysis of c‐Myc and hTERT protein expression in primary gastric cancer (P: average protein expression in primary gastric cancer samples) and local recurrent gastric cancer samples (1, 2, 3, 4, and 5). (B) Integrated optical density was measured to evaluate c‐Myc protein expression relative to β‐actin. (C) Integrated optical density was measured to evaluate hTERT protein expression relative to β‐actin. (D) Real‐time PCR of c‐Myc mRNA expression in primary gastric cancer (Primary: average mRNA expression in primary gastric cancer samples) and local recurrent gastric cancer samples (Local recurrent) (*P < 0.05). (E) Real‐time PCR of hTERT mRNA expression in primary gastric cancer (Primary: average mRNA expression in primary gastric cancer samples) and local recurrent gastric cancer samples (Local recurrent) (**P < 0.05).
Figure 2Acidified bile acids promote a malignant phenotype in MGC803 cells dependent on c‐Myc activity in vitro. (A) Morphological changes in MGC803 cells following treatment with acidified bile acids (A+B) for different durations. (B) Cell viability of MGC803 cells (CON), MGC803 cells/10058‐F4 (c‐Myc inhibitor; CON+10058‐F4), MGC803‐resistant cells (A+B), and MGC803‐resistant cells/10058‐F4 (A+B+10058‐F4) by the CCK‐8 assay. (C) Flow cytometry apoptosis assay. (D) Apoptosis rates of MGC803 cells, MGC803 cells/10058‐F4, MGC803‐resistant cells, and MGC803‐resistant cells/10058‐F4). (E) Colony formation assay. (F) Colony formation rates of MGC803 cells, MGC803 cells/10058‐F4, MGC803‐resistant cells, and MGC803‐resistant cells/10058‐F4). (*P < 0.05: MGC803 cells vs. MGC803‐resistant cells; **P < 0.05: MGC803‐resistant cells/DMSO vs. MGC803‐resistant cells/10058‐F4; ***P > 0.05: MGC803 cells versus MGC803 cells/10058‐F4).
Figure 3Acidified bile acids promote MGC803 xenograft formation and telomerase activity dependent on c‐Myc activity in vivo. (A) Growth curves of MGC803 (CON), MGC803+10058‐F4 (CON+10058‐F4), MGC803‐resistant (A+B), and MGC803‐resistant/10058‐F4 (A+B+10058‐F4) xenografts. (B) Tumor weight of MGC803 (CON), MGC803+10058‐F4 (CON+10058‐F4), MGC803‐resistant (A+B), and MGC803‐resistant/10058‐F4 (A+B+10058‐F4) xenografts. (C) Real‐time PCR of c‐Myc mRNA expression in MGC803 (CON), MGC803+10058‐F4 (CON+10058‐F4), MGC803‐resistant (A+B), and MGC803‐resistant/10058‐F4 (A+B+10058‐F4) xenografts. (D) Real‐time PCR of hTERT mRNA expression in MGC803 (CON), MGC803+10058‐F4 (CON+10058‐F4), MGC803‐resistant (A+B), and MGC803‐resistant/10058‐F4 (A+B+10058‐F4) xenografts. (E) Western blot analysis of c‐Myc and hTERT protein expression in MGC803 (CON), MGC803+10058‐F4 (CON+10058‐F4), MGC803‐resistant (A+B), and MGC803‐resistant/10058‐F4 (A+B+10058‐F4) xenografts. (F) Integrated optical density was measured to evaluate c‐Myc protein expression relative to β‐actin. (G) Integrated optical density was measured to evaluate hTERT protein expression relative to β‐actin. (H) Telomerase activity in MGC803 (CON), MGC803+10058‐F4 (CON+10058‐F4), MGC803‐resistant (A+B), and MGC803‐resistant/10058‐F4 (A+B+10058‐F4) xenografts by stretch PCR. (*P < 0.05: MGC803 cells vs. MGC803‐resistant cells; **P < 0.05: MGC803‐resistant cells/DMSO versus MGC803‐resistant cells/10058‐F4; ***P > 0.05: MGC803 cells versus MGC803 cells/10058‐F4). DMSO, dimethyl sulfoxide.
The relative activity of telomerase in different cells
| Groups | Telomere activity intensity ratio |
|
|
|---|---|---|---|
| CON+10058‐F4 | 1.101 ± 0.058 | 2.563 | 0.0625 |
| CON | 1.000 ± 0.036 | ||
| A+B+10058‐F4 | 2.053 ± 0.054 | 9.682 | 0.0006 |
| A+B | 2.534 ± 0.067 | 34.93 | 0.0001 |
CON versus A+B.
A+B versus A+B+10058‐F4.
CON versus CON+10058‐F4.